{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:48:48Z","timestamp":1775695728203,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T00:00:00Z","timestamp":1635638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40262-021-01071-5","type":"journal-article","created":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T05:02:47Z","timestamp":1635656567000},"page":"387-400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis"],"prefix":"10.1007","volume":"61","author":[{"given":"Li","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holly","family":"Kimko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Cimbora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliezer","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,31]]},"reference":[{"issue":"9","key":"1071_CR1","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):810\u20135.","journal-title":"Lancet Neurol"},{"issue":"7","key":"1071_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","volume":"6","author":"S Jarius","year":"2010","unstructured":"Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6(7):383\u201392.","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"1071_CR3","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1073\/pnas.1017385108","volume":"108","author":"N Chihara","year":"2010","unstructured":"Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Nat Acad Sci USA. 2010;108(9):3701\u20136.","journal-title":"Nat Acad Sci USA"},{"issue":"10206","key":"1071_CR4","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett J, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet. 2019;394(10206):1352\u201363.","journal-title":"Lancet"},{"key":"1071_CR5","unstructured":"SAS Software version 9.3, SAS Institute Inc, Cary, NC, United States. 2020."},{"issue":"7","key":"1071_CR6","doi-asserted-by":"publisher","first-page":"e51","DOI":"10.1038\/psp.2013.26","volume":"2","author":"W Byon","year":"2013","unstructured":"Byon W, Smith MK, Chan P, Tortorici MA, Riley S, Dai H, et al. Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. CPT Pharmacometrics Syst Pharmacol. 2013;2(7):e51.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"1071_CR7","unstructured":"Beal S, Boeckmann A, Bauer R, Sheiner LB. NONMEM User's Guides. (1989\u20132009) Icon Development Solutions, Ellicott City, MD, USA. 2009"},{"issue":"1","key":"1071_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1999","unstructured":"Jonsson EN, Karlsson MO (1999) Xpose\u2014an S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 58(1):51\u201364","journal-title":"Comput Methods Programs Biomed."},{"issue":"2","key":"1071_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)\u2013a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75(2):85\u201394.","journal-title":"Comput Methods Programs Biomed"},{"key":"1071_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s40262-019-00738-4","volume":"58","author":"L Yan","year":"2019","unstructured":"Yan L, Wang B, Chia YL, Roskos LK. Population pharmacokinetic modeling of benralizumab in adult and adolescent patients with asthma. Clin Pharmacokinet. 2019;58:943\u201358.","journal-title":"Clin Pharmacokinet"},{"key":"1071_CR11","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1111\/bcp.13271","volume":"83","author":"S Rozman","year":"2017","unstructured":"Rozman S, Grabnar I, Novakovi\u0107 S, Mrhar A, Jezer\u0161ek NB. Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome. Br J Clin Pharmacol. 2017;83:1782\u201390.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1071_CR12","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","volume":"126","author":"P Schober","year":"2018","unstructured":"Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126(5):1763\u20138.","journal-title":"Anesth Analg"},{"issue":"2","key":"1071_CR13","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"issue":"1","key":"1071_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1124\/jpet.110.168062","volume":"335","author":"R Herbst","year":"2010","unstructured":"Herbst R, Wang Y, Gallagher S, Mittereder N, Kuta E, et al. B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody. J Pharmacol Exp Ther. 2010;335(1):213\u201322.","journal-title":"J Pharmacol Exp Ther"},{"key":"1071_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.intimp.2016.04.035","volume":"36","author":"S Gallagher","year":"2016","unstructured":"Gallagher S, Turman S, Yusuf I, Akhgar A, Wu Y, et al. Pharmacological profile of MEDI-551, a novel anti-CD19 antibody, in human CD19 transgenic mice. Int Immunopharmacol. 2016;36:205\u201312.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1071_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10928-009-9142-8","volume":"37","author":"X Yan","year":"2010","unstructured":"Yan X, Mager DE, Krzyzanski W. Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn. 2010;37(1):25\u201347.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"12","key":"1071_CR17","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1177\/0091270011430506","volume":"52","author":"J Li","year":"2012","unstructured":"Li J, Zhi J, Wenger M, Valente N, Dmoszynska A, Robak T, et al. Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. J Clin Pharmacol. 2012;52(12):1918\u201326.","journal-title":"J Clin Pharmacol"},{"key":"1071_CR18","unstructured":"Rituximab [package insert]. San Francisco, CA: Biogen Idec Inc. and Genentech, Inc.; 2012."},{"key":"1071_CR19","unstructured":"Ocrelizumab [package insert]. South San Francisco, CA: Genetech, Inc.; 2020."},{"issue":"1","key":"1071_CR20","first-page":"2375","volume":"6","author":"B Wang","year":"2004","unstructured":"Wang B, Arends R, Roskos LK. A preliminary population pharmacokinetic analysis of panitumumab, a fully human IgG2 anti-EGFR monoclonal antibody. AAPS J. 2004;6(1):2375.","journal-title":"AAPS J"},{"issue":"6","key":"1071_CR21","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/bcp.12725","volume":"80","author":"PG Baverel","year":"2015","unstructured":"Baverel PG, Jain M, Stelmach I, She D, Agoram B, Sandbach S, et al. Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing. Br J Clin Pharmacol. 2015;80(6):1337\u201349.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"1071_CR22","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1365-2125.2010.03647.x","volume":"69","author":"CK Oh","year":"2010","unstructured":"Oh CK, Faggioni R, Jin F, Roskos LK, Wang B, Birrell C, et al. An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males. Br J Clin Pharmacol. 2010;69(6):645\u201355.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1071_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/psp4.12245","volume":"7","author":"B Wang","year":"2018","unstructured":"Wang B, Wu CY, Jin D, Vicini P, Roskos L. Model-based discovery and development of biopharmaceuticals: a case study of mavrilimumab, DModel based discovery and development of biopharmaceuticals: a case study of mavrilimumab. CPT Pharmacometrics Syst Pharmacol. 2018;7(1):5\u201315.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"4","key":"1071_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/cpt.986","volume":"103","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Narwal R, Jin C, Baverel PG, Jin X, Gupta A, et al. Population modeling of tumor kinetics and overall survival to identify prognostic and predictive biomarkers of efficacy for durvalumab in patients with urothelial carcinoma. Clin Pharmacol Ther. 2018;103(4):643\u201352.","journal-title":"Clin Pharmacol Ther"},{"key":"1071_CR25","unstructured":"US Food and Drug Administration. Guidance for industry: population pharmacokinetics. Rockville, MD: US FDA; 1999."},{"key":"1071_CR26","unstructured":"European Medicines Agency. Guideline on reporting the results of population pharmacokinetic analyses. London: EMA. 2007. https:\/\/www.ema.europa.eu\/en\/reporting-results-population-pharmacokinetic-analyses."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01071-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-021-01071-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-021-01071-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T05:04:54Z","timestamp":1646283894000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-021-01071-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,31]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1071"],"URL":"https:\/\/doi.org\/10.1007\/s40262-021-01071-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,31]]},"assertion":[{"value":"23 August 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This analysis was funded by Viela Bio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Li Yan, Daniel Cimbora, Eliezer Katz and William A. Rees are employees of Viela Bio. Holly Kimko and Bing Wang received financial assistance from Viela Bio.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data and material that support the findings of this study are available from the corresponding author upon reasonable request. Some data may not be made available because of privacy or ethical restrictions.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"LY and BW wrote the manuscript. EK, WAR, DC and LY designed the research. LY, HK, BW, WAR, EK and DC interpreted the data. HK, BW and LY analyzed the data.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}